Blueprint Medicines Corp (BPMC) : Hershey Trust Co added new position in Blueprint Medicines Corp during the most recent quarter end. The investment management firm now holds 299 shares of Blueprint Medicines Corp which is valued at $6,414 , the company said in a statement filed on Jul 21, 2016 with the SEC.
Other Hedge Funds, Including , Simplex Trading added BPMC to its portfolio by purchasing 76 company shares during the most recent quarter which is valued at $1,592. Gierl Augustine Investment Management Inc added BPMC to its portfolio by purchasing 100 company shares during the most recent quarter which is valued at $2,022. Hamilton Lane Advisors added BPMC to its portfolio by purchasing 21,034 company shares during the most recent quarter which is valued at $425,307. Blueprint Medicines Corp makes up approx 0.20% of Hamilton Lane Advisors’s portfolio. Bnp Paribas Arbitrage Sa added BPMC to its portfolio by purchasing 784 company shares during the most recent quarter which is valued at $16,684.
Blueprint Medicines Corp closed down -0.21 points or -0.97% at $21.54 with 54,763 shares getting traded on Thursday. Post opening the session at $21.46, the shares hit an intraday low of $21.11 and an intraday high of $22.06 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Blueprint Medicines Corp reported $-0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.19 according to the earnings call on May 10, 2016. Analyst had a consensus of $-0.76. The company had revenue of $6.90 million for the quarter, compared to analysts expectations of $3.24 million. The company’s revenue was up 961.5% compared to the same quarter last year.
Many Wall Street Analysts have commented on Blueprint Medicines Corp. Raymond James Initiated Blueprint Medicines Corp on May 27, 2016 to “Outperform”, Price Target of the shares are set at $23.
Blueprint Medicines Corporation (Blueprint) is a biopharmaceutical company. The Company is focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. The Company developed a molecule drug pipeline in cancer and a genetic disease. Its lead drug candidate BLU-285 targets KIT Exon 17 and PDGFRa D842V active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. The Company’s BLU-285 is developed for patients with systemic mastocytosis (SM) and defined subsets of patients with gastrointestinal stromal tumor (GIST). The Company’s Imatinib which is an inhibitor of KIT and PDGFRa is approved in SM and GIST. The Company’s other drug candidate is BLU-554 which targets FGFR4 a kinase that is activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma. The Company is also developing a drug candidate to target both RET and RET resistant mutants.